Which drug, and when, for patients with BRAF-mutant melanoma?

Abstract excerpt

Patients with metastatic melanoma had few treatment options until 2011, when two drugs-ipilimumab and vemurafenib-were approved following advances in the understanding of melanoma biology and tumour immunology. Almost 50% of melanomas harbour mutations in BRAF, mainly at codon 600, which result in constitutive activation of the MAPK pathway. The selective inhibitors of mutant BRAF Val600, vemurafenib and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Imidazoles
• Share to Indoles
• Share to Ipilimumab